Cognitive Impairment and Upper Extremity Performance in COPD (COPD)

Comparison of Upper Extremity Functional Capacity, Respiratory Functions, Fatigue and Quality of Life in Chronic Obstructive Pulmonary Patients With and Without Cognitive Impairment

Within the scope of this study, COPD patients will be divided into two groups according to cognitive dysfunction.

Pulmonary function test, COPD assessment scale, Mini-Mental State Examination and Montreal Cognitive Assessment Scale, 6 min pegboard ring test, grip strength measurement, Fatigue Impact Scale and St.George Respiratory Questionnaire will be applied to the groups.

Study Overview

• Status: Not yet recruiting
• Conditions: Cognitive Impairment; COPD; Upper Extremity; Upper Limb Function
• Intervention / Treatment: Other: Functional tests

Detailed Description

Although the mechanism of cognitive dysfunction in COPD is not clear, the reasons focused on are; decreased oxygen use, high carbon dioxide levels, increased inflammation and oxidative stress, decreased physical activity, peripheral vascular diseases, atherosclerosis, high or low blood pressure, cerebral vasoconstriction, increased intracranial pressure, accompanying comorbidities, smoking and genetic predisposition, brain damage and exacerbations have been reported. Few studies have shown that cognitive dysfunction is associated with functional performance. There are no studies on the effect of cognitive function on upper extremity performance and mechanisms of action in COPD patients.

The aim of this study is to compare upper extremity functional capacities, respiratory functions, fatigue and quality of life in COPD patients with and without cognitive function impairment.

Within the scope of this study, COPD patients will be divided into two groups according to cognitive dysfunction.

Pulmonary function test, COPD assessment scale, Mini-Mental State Examination and Montreal Cognitive Assessment Scale, 6 min pegboard ring test, grip strength measurement, Fatigue Impact Scale and St.George Respiratory Questionnaire will be applied to the groups.

• Study Type: Observational
• Enrollment (Anticipated): 80

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 45 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: N/A
• Genders Eligible for Study: All

• Sampling Method: Non-Probability Sample

Study Population

COPD patients above 45 years

Description

Inclusion Criteria:

• Volunteering to participate in the study
• Stage 2-3-4 according to the GOLD classification in the 40-65 age range

Exclusion Criteria:

• Exacerbation of respiratory symptoms in the past 4 weeks (change in breathlessness and/or sputum volume/color, need for antibiotic treatment or need for hospitalization)
• Presence of asthma, unstable coronary heart disease, uncontrolled diabetes, hypertension, left-sided congestive heart failure, neoplasia, severe claudication, encephalitis or epilepsy
• Having a history of head trauma or brain tumor
• Having a significant psychiatric condition or the presence of defined dementia, according to the American Psychiatric Association

Study Plan

How is the study designed?

Number of groups / cohorts

2

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
With cognitive impairment; Pulmonary function test, COPD assessment scale, Mini-Mental State Examination and Montreal Cognitive Assessment Scale, 6 min pegboard ring test, grip strength measurement, Fatigue Impact Scale and St.George Respiratory Questionnaire will be applied to the group.	Other: Functional tests; We will apply upper extremity performance tests, hand grip measurements, and scales measuring fatigue and quality of life to the groups.
without cognitive impairment; Pulmonary function test, COPD assessment scale, Mini-Mental State Examination and Montreal Cognitive Assessment Scale, 6 min pegboard ring test, grip strength measurement, Fatigue Impact Scale and St.George Respiratory Questionnaire will be applied to the group.	Other: Functional tests; We will apply upper extremity performance tests, hand grip measurements, and scales measuring fatigue and quality of life to the groups.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
6 min. pegboard ring test	It is used to measure upper extremity functional capacity.	6 minutes

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Mini Mental State Test	It is used for measuring cognitive impairment	15 minutes
Montreal Cognitive Assessment Scale	It is used for measuring cognitive impairment	30 minutes
Respiratory Function Test	It is used for measuring lung functions and respiratory muscle strength	20 minutes
Fatigue Impact Scale	It is used for measuring fatigue level	Time Frame: 20 minutes
St. George Respiratory Questionnaire	It is used for measuring desase-related quality of life	20 minutes
COPD Assessment Test	It is used for measuring health status of COPD patients	10 minutes
mMRC Dyspnea Scale	It is used for measuring dyspnea sensation in daily living activities	5 minutes

Collaborators and Investigators

• Sponsor: Izmir Katip Celebi University

Study record dates

Study Major Dates

• Study Start (Anticipated): November 19, 2021
• Primary Completion (Anticipated): June 30, 2022
• Study Completion (Anticipated): July 30, 2022

Study Registration Dates

• First Submitted: November 18, 2021
• First Submitted That Met QC Criteria: November 18, 2021
• First Posted (Actual): November 30, 2021

Study Record Updates

• Last Update Posted (Actual): November 30, 2021
• Last Update Submitted That Met QC Criteria: November 18, 2021
• Last Verified: November 1, 2021

More Information

Terms related to this study

• Keywords: cognition; cognitive impairment; upper extremity; copd
• Additional Relevant MeSH Terms: Mental Disorders; Neurocognitive Disorders; Cognition Disorders; Cognitive Dysfunction
• Other Study ID Numbers: IKC125

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No